Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Study of Pazopanib as Front-Line Therapy in Patients With Non-Resectable or Metastatic Soft Tissue Sarcomas Who Are Not Candidates for Chemotherapy

NCT02300545 is registered in ClinicalTrials.gov with Washington University School of Medicine as lead sponsor.

NCT NCT02300545
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02300545 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Study of Pazopanib as Front-Line Therapy in Patients With Non-Resectable or Metastatic Soft Tissue Sarcomas Who Are Not Candidates for Chemotherapy
Lead sponsor
Washington University School of Medicine
Phase
Phase 2
Overall status
Completed
Start date
April 8, 2015
Completion date
July 11, 2020
Enrollment
56 (actual)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

sarcoma, soft tissue, soft tissue sarcoma